Saniona publicerar sin delårsrapport för det första kvartalet 2021
26 mai 2021 02h00 HE
|
Saniona AB
PRESSMEDDELANDE 26 maj 2021 Jan – mar 2021 (jan – mar 2020) Intäkter uppgick till 3,4 MSEK (2,3 M)Rörelseresultat uppgick till -94,1 MSEK (-27,4 M)Periodens resultat uppgick till -83,4 MSEK (43,2...
Saniona publishes its interim report for the first quarter of 2021
26 mai 2021 02h00 HE
|
Saniona AB
PRESS RELEASE May 26, 2021 Q1 2021 (Q1 2020) Revenue was SEK 3.4 M (2.4 M)Operating loss was SEK -94.1 (-27.4 M)Net profit/loss was SEK -83.4 M (43.2 M)Earnings per share were SEK -1.34...
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
25 mai 2021 16h01 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS)....
Saniona har genomfört en Forsknings- och Utvecklingsdag om bolagets pipelineprogram inom jonkanaler
20 mai 2021 14h30 HE
|
Saniona AB
PRESSMEDDELANDE 20 maj 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, genomförde en digital FoU-dag idag. Under evenemanget...
Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs
20 mai 2021 14h30 HE
|
Saniona AB
PRESS RELEASE May 20, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it...
Saniona anordnar Forsknings- och Utvecklingsdag om hur expertis inom jonkanaler kan utnyttjas för att behandla sällsynta sjukdomar
12 mai 2021 08h00 HE
|
Saniona AB
PRESSMEDDELANDE 12 maj 2021 Det digitala evenemanget äger rum torsdagen 20 maj 2021, kl. 11.00 EDT / 17.00 CEST Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad...
Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases
12 mai 2021 08h00 HE
|
Saniona AB
PRESS RELEASE May 12, 2021 Virtual event will take place on Thursday, May 20, 2021, at 11:00 am EDT / 17:00 CEST Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
11 mai 2021 07h00 HE
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics
10 mai 2021 08h30 HE
|
Gennao Bio
~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...
Saniona lanserar ny videoserie för att belysa hur Prader-Willis syndrom och hypotalamisk fetma drabbar patienter och anhöriga
10 mai 2021 08h00 HE
|
Saniona AB
PRESSMEDDELANDE 10 maj 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännager idag videoserien ”Saniona’s Community Voices”,...